Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2015-07-16

Clinical Trial Update: Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005) [Phase 3]

View source ↗

Summary

Bayer’s Phase 3 trial MK-8114-005 evaluating polyethylene glycol 3350 (PEG 3350) for relief of constipation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Polyethylene glycol 3350 (polyethylene glycol 3350)

Snippet

Sponsor: Bayer | Conditions: Constipation | Phase 3 | Status: WITHDRAWN